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This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).SUMMARYGlioblastoma (GBM)-derived tumorigenic stem-like cells (GSCs)may play a key role in therapy resistance. Previously, we reported that the
mitotic kinase MELK binds and phosphorylates the oncogenic transcription factor FOXM1 in GSCs. Here, we demonstrate that the cat-
alytic subunit of Polycomb repressive complex 2, EZH2, is targeted by the MELK-FOXM1 complex, which in turn promotes resistance to
radiation in GSCs. Clinically, EZH2 and MELK are coexpressed in GBM and significantly induced in postirradiation recurrent tumors
whose expression is inversely correlated with patient prognosis. Through a gain-and loss-of-function study, we show that MELK or
FOXM1 contributes to GSC radioresistance by regulation of EZH2. We further demonstrate that the MELK-EZH2 axis is evolutionarily
conserved inCaenorhabditis elegans. Collectively, these data suggest that theMELK-FOXM1-EZH2 signaling axis is essential for GSC radio-
resistance and therefore raise the possibility that MELK-FOXM1-driven EZH2 signaling can serve as a therapeutic target in irradiation-
resistant GBM tumors.INTRODUCTION
Glioblastoma (GBM) is the most common primary malig-
nant brain tumor and the median survival of patients is
less than 2 years (Brennan et al., 2013). The current stan-
dard of therapy involves maximal surgical resection fol-
lowed by radiotherapy and chemotherapy. However, this
treatment strategy fails to eliminate a subset of tumor cells
that escape from therapeutic insult and result in tumor
recurrence, leading to reduced survival in these patients.
A GBM tumor is composed of heterogeneous tumor cell
populations that include tumor cells with stem cell proper-
ties, termed glioma stem-like cells (GSCs) (Hemmati et al.,
2003; Singh et al., 2004). Accumulating evidence indicates
that GSCs contribute to radioresistance and subsequent tu-
mor cell repopulation, resulting in recurrent tumors (Bao
et al., 2006). Therefore, it is critical to elucidate the molec-
ular mechanisms underlying the radioresistance of GSCs.
Maternal embryonic leucine-zipper kinase (MELK) is a
serine/threonine kinase and is abundantly expressed in
GBM and various other cancers (Gu et al., 2013; Joshi
et al., 2013; Minata et al., 2014; Nakano et al., 2008,
2011). We previously reported that MELK is highly ex-
pressed in GSCs and its mRNA expression is inversely
correlated with the survival of GBM patients (Gu et al.,
2013; Nakano et al., 2008). In addition, short hairpin
RNA (shRNA)-mediated MELK elimination induces GSC226 Stem Cell Reports j Vol. 4 j 226–238 j February 10, 2015 j ª2015 The Aapoptosis with less inhibitory effects on normal neural pro-
genitor cells (NPCs) (Nakano et al., 2005). Mechanistically,
MELK associates with two oncogenic transcription factors
(c-JUN and FOXM1) inGSCs, but not their normal counter-
parts, which explains at least in part the cancer-specific,
survival-promoting function of MELK (Gu et al., 2013;
Joshi et al., 2013). Nonetheless, the pathophysiological
roles of MELK in GSC radioresistance remain elusive.
Polycomb group (PcG) proteins are important epigenetic
regulators of embryonic development and the cell fate de-
cision (Aloia et al., 2013). PcG proteins play a crucial role
in mediating global transcriptional repression as two large
protein assemblies termed Polycomb repressive complex 1
(PRC1) and PRC2 (Aloia et al., 2013; Margueron and Rein-
berg, 2011). The core components of PRC2 include EZH2
(enhancer of Zeste homolog 2), Suz12 (suppressor of Zeste
12), and EED (embryonic ectoderm development). In
particular, EZH2 functions as a lysine methyltransferase,
and EZH2-containing PRC2 catalyzes trimethylation of his-
tone 3 at lysine 27 (H3K27me3) (Margueron and Reinberg,
2011). In a wide range of cancers, including GBM, elevated
expression of EZH2 is well recognized and its expression is
strongly linked to tumor malignancy and invasiveness
(Kim et al., 2013; Radulovic et al., 2013). Recent studies,
including ours (Kim et al., 2013; Lee et al., 2008), suggested
that EZH2 plays a critical role in GSC maintenance and
GBM propagation similar to the function of MELK inuthors
GSCs. These studies prompted us to speculate that MELK
and EZH2 may be involved in the same signaling pathway
in GSCs. In this study, we tested the hypothesis that
MELK is an upstream regulator of EZH2 signaling to pro-
mote GSC survival and resistance to radiation therapy on
GBM tumors and GSCs.RESULTS
MELK and EZH2 Are Colocalized in GBM Cells and
Upregulated after Radiation Treatment
To investigate whether MELK and EZH2 could potentially
interact, we first performed immunofluorescence and
examined their localization. As shown in Figure 1A,
MELK+ cells exhibited high immunoreactivity to EZH2
and the two proteins colocalized. A strong correlation be-
tween MELK and EZH2 protein expression in GBM tumors
was also observed in tissue microarray (n = 76) patient
samples and western blot analyses (n = 17) (Figure 1B
and Figure S1A). At the mRNA level, a statistically signifi-
cant correlation between MELK and EZH2 expression
was found in high-grade gliomas (HGGs) (Figure 1C). A
strong correlation between MELK and EZH2 was also
observed when they were examined in three glioma
data sets (Freije et al., 2004; Sun et al., 2006; Verhaak
et al., 2010; https://tcga-data.nci.nih.gov/docs/publications/
gbm_exp/) (Figure S1B). Intriguingly, when expression of
MELK and EZH2 was compared between newly diagnosed,
untreated GBM tumors and recurrent GBM tumors after
failed radiation and chemotherapy, both of these proteins
were markedly upregulated in recurrent tumors (Mao
et al., 2013; Phillips et al., 2006; http://www.ncbi.nlm.
nih.gov/geo/query/acc.cgi?acc=GSE4271) (Figures 1D and
S1C). When GBM tumors were divided into two groups
based on patient survival time after diagnosis, both
MELK and EZH2 were considerably elevated in patients
with a worse prognosis (Figure 1E). To corroborate these re-
sults with the immunohistochemical findings in recurrent
GBM tumors, we irradiated three glioma sphere samples
(GBM83, GBM1123, and GBM528) (Mao et al., 2013).
We observed a substantial increase in both the mRNA
expression and protein levels of MELK and EZH2 in vitro
(Figures 1F, 1G, and S1D). Interestingly, postirradiation
(post-IR) upregulation of MELK and EZH2 was also
observed in nontumorigenic differentiated glioma sphere
samples (GBM83 and GBM1123) (Figure S2). In addition,
GSC-derived xenograft tumors in mice showed an eleva-
tion of these two proteins after IR treatment in vivo (Fig-
ure 1H). Collectively, MELK and EZH2 are colocalized in
a subset of GBM tumor cells, and both the mRNA and pro-
tein expressions of these genes are upregulated in GBM
tumors and GSCs after IR.Stem CellMELK-Mediated EZH2 Signaling Is Required for GSC
Radioresistance
In a recent study (Gu et al., 2013), we demonstrated that
MELK downregulation induces a loss of the stem cell
phenotype with subsequent tumor cell differentiation
and reduced clonogenicity and tumorigenicity in GBM
cells. Given the IR-induced substantial upregulation of
MELK in GBM spheres, we postulated that MELK may pro-
tect against IR-induced GSC death. To test this possibility,
we combined IR treatment with MELK overexpression,
followed by fluorescence-activated cell sorting (FACS)
analysis for cellular apoptosis in GBM83 and GSC23
spheres (Bhat et al., 2013; Mao et al., 2013) using Annexin
V and propidium iodide. As expected, MELK overex-
pression partially restored IR-induced apoptotic popula-
tions (Figure 2A). On the other hand, MELK knockdown
by shRNA resulted in an increased number of apoptotic
cells (Figure S3). Interestingly, when these GBM spheres
were pretreated with an EZH2 inhibitor, GSK126, rescue
of GBM sphere apoptosis mediated by MELK overex-
pression was almost completely attenuated (Figure 2A),
indicating a possible MELK-mediated EZH2 signaling axis
in GSC survival after IR-induced cellular damage, at least
in vitro.
Next, we assessed the effect of combining MELK
silencing with IR treatment for GBM sphere-derived mouse
tumors in vivo. For this experiment, we used luciferase-en-
gineered GSC23 spheres (Bhat et al., 2013). After shMELK
infection, dissociated GSC23 spheres were xenografted
into mouse brains and treated with fractionated doses of
IR (4 3 2.5 Gy) (Figure 2B). Tumor growth was then fol-
lowed by bioluminescence imaging. Unlike the tumors in
controlmicewith nontarget shRNA, GSC23 sphere-derived
tumors treated with MELK knockdown followed by IR dis-
played substantially reduced sizes at day 42 after xenograft-
ing. Subsequently, prolonged survival of tumor-bearing
mice by IR was strongly enhanced by MELK silencing in
GSC23 spheres (average prolonged survival of 13 days in
the shNT [control] group versus 27 days in the shMELK
group; Figure 2C). Taken together, these data suggest that
post-IR MELK upregulation promotes tumorigenesis and
propagation in vivo.
MELK and EZH2 Have Evolutionarily Conserved
Functions in Radioprotection
MELK and EZH2 are highly conserved in both mamma-
lian and nonmammalian multicellular species. Therefore,
we asked whether the MELK and EZH2 homologs found
in the nematode Caenorhabditis elegans also function in
IR-induced DNA damage responses. The C. elegans germ-
line is an established model for studying DNA damage
response mechanisms as well as stem cell proliferation
and survival in vivo (Garvin et al., 1998). The adultReports j Vol. 4 j 226–238 j February 10, 2015 j ª2015 The Authors 227
Figure 1. MELK and EZH2 Are Colocalized in GBM Cells and Upregulated after Radiation Treatment
(A) Immunostaining for EZH2 (green) and MELK (red) in GBM tumors. Nuclei were stained with Hoechst (blue). Scale bar represents 25 mm.
(B) Correlation of MELK and EZH2 protein expression by microarray analysis of HGGs (n = 76).
(C) Correlation of MELK and EZH2 mRNA expression by microarray analysis of HGGs (n = 76).
(D) Immunohistochemistry for MELK and EZH2 in newly diagnosed (ND, n = 65) or recurrent (Rec, n = 41) tumors, with corresponding
quantification of cells (%) immunoreactive against each protein. Bottom two panels: quantification of MELK+ and EZH2+ cells in ND and
Rec tumors analyzed with ImageJ software. Scale bar represents 50 mm. Asterisk (*) indicates statistical significance by Student’s two-
tailed t test; *p < 0.05. Arrow indicates postradiation vasculosclerosis.
(E) MELK and EZH2mRNA expression in patients with good (>209 weeks survival, n = 19) versus poor (<52 weeks survival, n = 17) prognosis
in the Phillips et al. (2006) data set. Asterisk (*) indicates statistical significance by Student’s two-tailed t test; *p < 0.05.
(F) Relative mRNA expression levels (normalized to GAPDH) of MELK, FOXM1, and EZH2 in GBM83 glioma spheres at 24 and 48 hr after 6 Gy
radiation treatment. Data are represented as means ± SD of triplicate experiments.
(legend continued on next page)
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Figure 2. MELK-Mediated EZH2 Signaling Is Required for GSC Radioresistance
(A) Flow-cytometric analysis of GBM spheres for Annexin V and propidium iodide. Left panel: nonirradiated, EGFP-overexpressing control.
Left middle panel: irradiated, EGFP-overexpressing control. Right middle panel: irradiated, MELK-overexpressing GSCs. Right panel:
irradiated, MELK-overexpressing GSCs treated with the EZH2 inhibitor GSK126.
(B) Bioluminescence imaging (left panel) and average radiance (right panel) of tumor growth after infection with shNT (nontarget control,
n = 5) or shMELK (n = 5), followed by treatment with or without fractionated doses of radiation (4 3 2.5 Gy). Error bar indicates ± SEM;
p values were calculated by Student’s two-tailed t test.
(C) Kaplan-Meier survival curves of tumor-burden mice with the indicated treatments as shown in (B).
See also Figure S3.hermaphrodite germline consists of two symmetrical
U-shaped tubular structures in which a population of
proliferating mitotic cells creates a stem cell niche at the
distal end (Figure 3A). The mitotic cells migrate proxi-
mally from the distal end, transition into meiosis and(G) Western blot analysis of EZH2 and MELK in GBM83 and GBM1123 gli
values below the blots indicate the relative expression levels of EZH2
(H) Western blot analysis of EZH2 and MELK in GSC-derived tumors a
See also Figures S1 and S2.
Stem Cellprogress through the stages of prophase I, and eventually
form oocytes at the proximal end of the tube. Under
physiological conditions, approximately half of the
germ cells undergo apoptosis, which is detectable in late
pachytene and early diplotene.oma spheres at 24, 48, and 72 hr after 6 Gy radiation treatment. The
and MELK protein in comparison with GAPDH.
t 0, 3, and 24 hr after in vivo IR.
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Figure 3. MELK/EZH2 Functions in Radioprotection Are Evolutionarily Conserved
(A) Schematic of C. elegans germline migration and development. The mitotic region is located at the distal end. Meiosis I begins at the
transition zone (TZ) and as the nuclei progress proximally, they enter pachytene, diplotene, and diakinesis. Oocytes mature in diakinesis
before being fertilized by sperm and becoming embryos.
(B) Quantification of mitotic cells in wild-type (N2) or pig-1 mutant. Two independent experiments were used for the quantification. Data
are represented as means ± SD; ***p < 0.001. Representative images of the mitotic region stained with DAPI are shown on the left.
Arrowhead indicates distal tip.
(C) Proportion of AO+ cells in wild-type (N2), pig-1, or mes-2 mutants with or without treatment with 20 Gy IR. Young adult worms were
treated with IR, rescued overnight, and then stained with AO. At least 15 gonads were counted for each strain and condition. The mes-2
(bn11) strain is either homozygous or heterozygous for the mes-2 allele. Two independent experiments were used for the quantification.
Representative images of AO-stained nuclei in the late pachytene/early diplotene region, where apoptosis occurs, are shown. Arrowheads
indicate AO-stained nuclei.
(D) Percent embryonic lethality in wild-type (N2), pig-1, or mes-2 mutants after treatment with 0, 60, or 120 Gy radiation. Synchronized
young adult worms were treated with IR and rescued overnight, and eggs were collected from at least 15 worms for 4–6 hr. The average of at
least three experiments is shown. Data are represented as means ± SD; nsp > 0.05, *p < 0.05, **p < 0.01.
(E) Relative pig-1 and mes-2 mRNA expression after IR, normalized to untreated wild-type worms. Total RNA was extracted 4 hr after young
adult worms were treated with 120 Gy IR. The graph is an average of at least three experiments performed on three separate days.
(F) Percent embryonic lethality in wild-type N2, pig-1, or mes-2 mutant lines with or without pig-1 RNAi knockdown followed by IR.
Synchronized L1 larvae were subjected to RNAi with pig-1 (RNAi) or control (RNAi) and treated with IR (60 Gy) as young adults. They were
then rescued overnight and eggs were collected from at least 15 worms for 4–6 hr. The graph is an average of at least three experiments
performed on three separate days, except for mes-2 (bn11); control (RNAi), which was repeated two times. Data are represented as
means ± SD; nsp > 0.05, *p < 0.05, **p < 0.01.
(G) Relative mes-2 mRNA expression in N2 or pig-1(gm344) mutant. Data represent the mean ± SD; *p < 0.05; p values were calculated by
Student’s two-tailed t test. The graph is an average of at least three experiments performed on three separate days.
See also Figure S4.The nematode EZH2homolog,MES-2, has an established
role in the germline (Garvin et al., 1998; Holdeman et al.,
1998), but the role of the MELK homolog, PIG-1, in germ
cells is unknown. The presence of pig-1 transcripts in
the germline, as revealed by in situ hybridization (NEXT230 Stem Cell Reports j Vol. 4 j 226–238 j February 10, 2015 j ª2015 The Adatabase, http://nematode.lab.nig.ac.jp/) and quantitative
RT-PCR (qRT-PCR) analysis (Figure S4), suggests that pig-1 is
expressed in the germline. Therefore, we utilized a mutant
strain containing the putative null allele gm344, which is a
524 bp deletion of the promoter region through part of theuthors
second exon, to determine whether pig-1 also has a func-
tional role in germ cells. DAPI staining of pig-1(gm344)
mutant germlines revealed a significant reduction in the
number of proliferating mitotic cells compared with age-
matched wild-type (N2) germlines (Figure 3B). pig-1 also
appears to negatively regulate germ cell apoptosis, as acri-
dine orange (AO) staining showed that pig-1(gm344) ani-
mals had a modest but consistent increase in apoptosis
compared with N2 animals (Figure 3C, compare the first
and third bars). These data suggest that pig-1 has conserved
functions in cell proliferation and apoptosis (Gu et al.,
2013; Joshi et al., 2013; Nakano et al., 2005, 2008, 2011).
When treated with IR, C. elegans germlines are known to
activate protective mechanisms, including mitotic cell-cy-
cle arrest, repair, and apoptosis. Therefore, we investigated
the effect of IR on the survival of embryos from animals
with genetic mutations in pig-1 or mes-2. Young adult
worms containing mature germlines were treated with
varying doses of IR and the numbers of hatched and un-
hatched progenywere counted to determine the rate of em-
bryonic lethality. Both pig-1(gm344) and mes-2(bn11)
mutant animals showed a dose-dependent increase in
embryonic lethality compared with wild-type control
(N2) animals (Figure 3D). Apoptosis was also significantly
higher in IR-treated pig-1(gm344) and mes-2(bn11) animals
compared with IR-treated N2 animals (Figure 3C). Similar
to what was observed for MELK, pig-1 transcript levels
increased after IR exposure (Figure 3E). These results indi-
cate that loss of either pig-1 ormes-2 leads to a compromised
response to IR exposure, resulting in increased germ cell
apoptosis as well as higher rates of embryonic lethality.
Next, to determine whether pig-1 andmes-2 act in a com-
monpathway or two parallel pathways, we investigated the
genetic interactions between these genes using RNAi. A
reduction of pig-1 expression by RNAi resulted in hypersen-
sitivity to IR to a degree similar to that observed in the
pig-1(gm344) mutant (compare the second and third bars
in Figure 3F), confirming that the IR-induced embryonic
lethality observed in this mutant is due to the loss of
pig-1. Downregulation of pig-1 in both the N2 and mes-
2(bn11) genetic backgrounds resulted in a similar percent-
age of embryonic lethality, suggesting that these two genes
act in the same pathway (Figure 3F). In agreement with
this, the level of mes-2 transcripts, as determined by qRT-
PCR, was decreased in pig-1 mutant worms in comparison
with N2 (Figure 3G). Together, these data indicate that the
biological functions and the relationship of MELK and
EZH2 are evolutionarily conserved.
EZH2 Is Transcriptionally Regulated byMELK in GBM
Spheres
We then sought to determine howMELK is associated with
EZH2 signaling in GSCs. When MELK was silenced inStem CellGBM83 spheres by shRNA, both themRNA and protein ex-
pressions of EZH2 were significantly decreased (Figures 4A
and 4B). However, mRNA expression was restored when
EZH2 was exogenously expressed in these MELK-silenced
cells (Figure 4A). We performed a luciferase assay to assess
the change in EZH2 promoter activity due to MELK over-
expression in GBM83 spheres. Overexpression of MELK
(coding region) increased EZH2 promoter activity, and
in turn this increasewas largely attenuated by either shRNA
targeting the 30 UTR of MELK (Figure 4C) or pharmacolog-
ical treatment with Compound 1 (C1, a MELK inhibitor)
(Figure 4D; Minata et al., 2014). Consistent with the
change in EZH2 mRNA expression and its promoter activ-
ity by MELK, flow cytometry with EZH2 antibody demon-
strated that EZH2 protein expression was decreased when
GBM83 spheres were passaged from serum-free neuro-
sphere (NS) medium to prodifferentiation conditions
(DC) (Figure 4E). This change in EZH2 expression was
largely, but not completely, restored by MELK overexpres-
sion, whereas pretreatment with GSK126 (an EZH2 inhibi-
tor) did not result in the same effect (Figure 4E). In turn,
shRNA-mediated MELK silencing alone was sufficient to
decreased EZH2 expression in GBM83 spheres, which was
recovered by combined EZH2 overexpression. Collectively,
these data suggest that EZH2 is transcriptionally regulated
by MELK in GSCs.
EZH2 Is a Direct Target of the MELK/FOXM1 Complex
in GBM Spheres
Since MELK is a protein kinase without DNA-binding
domains, an intermediate transcription factor may be
required to directly regulate the expression level of EZH2
transcripts. Therefore, we aimed to identify the direct regu-
latory molecule for EZH2 transcriptional activity in GSCs.
Our recent studies identified novel cancer-specific sub-
strates for MELK protein, including the Forkhead transcrip-
tion factor FOXM1 (Joshi et al., 2013). Similar to what was
observed for MELK and EZH2 (Figure 1C), the expression
profiles of FOXM1 in GBM tumors exhibited a statistically
significant correlation with those of EZH2 (Figure 5A).
The statistically significant correlation of FOXM1 and
EZH2 expression in glioma tumors was also observed in
other three data sets (Freije et al., 2004; Sun et al., 2006; Ver-
haak et al., 2010; https://tcga-data.nci.nih.gov/docs/
publications/gbm_exp/) (Figure S5). In addition, FOXM1
was significantly elevated in GBM patients with a worse
prognosis (Figure 5B). Therefore, we hypothesized that
FOXM1 may mediate the MELK-EZH2 signaling axis
in GSCs. shRNA-mediated FOXM1 knockdown decreased
EZH2 mRNA expression in GBM83 cells, which was
restored by EZH2 exogenous expression (Figure 5C).
In vitro luciferase reporter assay demonstrated that forced
expression of FOXM1 increased EZH2 promoter activityReports j Vol. 4 j 226–238 j February 10, 2015 j ª2015 The Authors 231
Figure 4. EZH2 Is Transcriptionally Regulated by MELK in GBM Spheres
(A) Heatmap of MELK and EZH2 expression in GBM83 spheres after treatment with shNT, shMELK, or shMELK plus EZH2 overexpression.
(B) Western blot for EZH2 in shMELK-infected GBM83 spheres. shNT was the control for MELK knockdown. GAPDH was the loading control.
(C) Relative chemiluminescence of luciferase driven by the EZH2 promoter after infection of GBM spheres with GFP control, MELK over-
expression vector, or MELK overexpression with shMELK. Data represent the mean ± SD of three independent experiments and statistical
significance was evaluated by one-way ANOVA followed by Bonferroni post hoc tests. *p < 0.05; **p < 0.01.
(D) Relative chemiluminescence of EZH2 promoter activity in GBM spheres after infection with GFP control or MELK overexpression vector
and increasing doses of the MELK inhibitor C1. Data represent the mean ± SD of three independent experiments and statistical significance
was evaluated by one-way ANOVA followed by Bonferroni post hoc tests. *p < 0.05; **p < 0.01.
(E) Flow-cytometric analysis of GBM83 spheres in neurosphere (NS) or differentiation (DC) medium. Analysis of spheres in DC medium also
included samples treated with MELK overexpression or MELK overexpression plus GSK126 (left panel). Spheres cultured in NS medium were
also treated with shMELK or shMELK plus EZH2 overexpression vector.in GBM83 spheres (Figure 5D). Of note, compared with
MELK (Figure 4), FOXM1 had a 3-fold greater impact on
EZH2 promoter activity. MELK silencing by shRNA sub-
stantially diminished FOXM1-driven EZH2 transcriptional
activity, whereas FOXM1 silencing had only a marginal
effect on MELK-driven EZH2 transcriptional activity in
GBM83 spheres. This result indicates that the action of
FOXM1 largely depends on MELK, but not vice versa, for
activation of the EZH2 promoter in GSCs. The FOXM1-
dependent transcriptional activity of EZH2 was also
confirmed by cotreatment with FOXM1 overexpression
and the FOXM1 inhibitor siomycin A (Figure 5E). At the
molecular level, both the MELK/FOXM1 protein complex
and the kinase-dependent phosphorylation of FOXM1
were essential for FOXM1-driven transcriptional activation
of EZH2, because MELK mutant protein lacking FOXM1
binding (D150A) and FOXM1 mutant protein lacking232 Stem Cell Reports j Vol. 4 j 226–238 j February 10, 2015 j ª2015 The Aphosphorylation (596/678), but not transactivation (715/
724) function, masked the transactivation of EZH2 tran-
scripts by MELK and FOXM1 (Figures 5F and 5G). These
results indicate that binding ofMELK to FOXM1 and subse-
quent phosphorylation of FOXM1 are essential for the
transcriptional activation of EZH2 in GSCs. We further
confirmed that FOXM1 occupies the genomic region that
regulates the EZH2 transcripts in GSCs by chromatin
immunoprecipitation (ChIP)-PCR (Figure 5H). In turn,
when these cells were pretreated with either MELK inhibi-
tor (C1) or FOXM1 inhibitor (siomycin A) (Gartel, 2013),
the occupancy of FOXM1 in the EZH2 promoter was
largely abolished, suggesting that the MELK-dependent
FOXM1 signals to drive EZH2 transcripts in GSCs (Fig-
ure 5I). To validate the MELK/FOXM1-mediated EZH2
signaling axis in GSCs, we performed a transcriptome
microarray followed by qRT-PCR validation with GBM83uthors
cells. As expected, all of the known EZH2 downstream
target genes, except for RUNX3, were strongly suppressed
by both MELK shRNA and FOXM1 shRNA, and the com-
bined expression of EZH2 with knockdown of either
MELK or FOXM1 restored their expression back to or nearly
to the basal levels (Figure 5J). Consistent with these mRNA
expression data, FACS analysis demonstrated that dimin-
ished EZH2 expression in differentiated GBM83 spheres
was partially restored by FOXM1 overexpression alone,
but not when combined with GSK126 (Figure 5K). In
turn, overexpression of both MELK and FOXM1 in these
cells completely restored EZH2 expression only in the
absence of GSK126, suggesting that in these GSC cultures,
MELK and FOXM1 are the predominant regulators of EZH2
transcriptional expression. Similarly to MELK knockdown,
FOXM1 knockdown significantly reduced EZH2 protein
levels, and when FOXM1 knockdown was combined with
exogenous expression of EZH2, the decrease in EZH2 was
restored to near basal levels. Lastly, we investigated
whether FOXM1 rescues IR-induced GSC apoptosis simi-
larly to MELK, and whether GSK126 treatment could also
mask this phenotype. As shown in Figure 5L, IR-induced
apoptosis was largely rescued by FOXM1 overexpression,
and cotreatment with GSK126 prevented apoptosis in
these stem cell populations.DISCUSSION
In this study, we report a number of findings: (1) in GBM
tumors, MELK and EZH2 proteins are mostly colocalized
in a subset of tumor cells; (2) the fraction of MELK+ and
EZH2+ cells preferentially increases in postradio-/chemo-
therapy recurrent GBM tumors compared with de novo
untreated tumors; (3) radioprotection of stem cells by the
MELK-EZH2 axis is evolutionarily conserved between
C. elegans and human; (4) in humanGBM, GSC radioresist-
ance depends largely on MELK-mediated EZH2 signaling
in vitro, and MELK knockdown using shRNA radiosensi-
tizes in vivo tumors; (5) EZH2 is a direct target of the
oncogenic transcription factor FOXM1 in GSCs; (6) signals
derived from the MELK/FOXM1 protein complex are both
sufficient and required to drive the transcriptional activity
of EZH2 in GSCs; and (7) clinically, MELK, FOXM1, and
EZH2 are strongly linked to GBM patient prognosis.
Our data provide evidence that the oncogenic protein
complex MELK/FOXM1 is a crucial transcriptional regu-
lator of EZH2. EZH2, a lysine methyltransferase of
PRC2, mediates the transcriptional repression of prodiffer-
entiation genes in neoplastic stem cells (Margueron and
Reinberg, 2011; Richly et al., 2011; Sparmann and van Lo-
huizen, 2006).While the oncogenic role of EZH2 in various
cancers as a transcriptional silencer is well established, itStem Cellremains elusive how the EZH2 gene is transcriptionally
regulated in GSCs and whether EZH2 upregulation is asso-
ciated with radioresistance of cancers. Recently, a few tran-
scription activators, including E2F1, Sox4, and miR-101,
were implicated in the transcriptional control of EZH2
(Smits et al., 2010; Tiwari et al., 2013). However, whether
these factors play a role in GBM and GSCs requires further
investigation.
UsingC. elegans as amodel system, we also demonstrated
that the functional relationship between MELK and EZH2
is evolutionarily conserved. While the role of MES-2
(ortholog of EZH2 in C. elegans) in germ cells has been pre-
viously described (Garvin et al., 1998; Holdeman et al.,
1998), we show that the pig-1 (ortholog of MELK in
C. elegans) gene has a functional role in the C. elegans germ-
line.We found that the loss of pig-1 resulted in a significant
decrease in the number of proliferatingmitotic cells, as well
as an increase in apoptosis under physiological conditions.
Previously, pig-1 was implicated in the regulation of the
developmental cell death pathway in young larvae and em-
bryos (Chien et al., 2013; Cordes et al., 2006). In this
context, pig-1 supports apoptosis in somatic cells, suggest-
ing that pig-1 may have opposite roles in somatic versus
germ cells or in cells with diverse differentiation states, as
also suggested by several studies in mammalian cells (Joshi
et al., 2013; Nakano et al., 2005). Furthermore, pig-1 and
mes-2 mutant animals showed an increase in both the
rate of apoptosis and embryonic lethality after IR in
comparison with wild-type worms. A genetic interaction
analysis suggested that pig-1 and mes-2 act through a com-
mon pathway and that mes-2 mRNA levels are decreased
in pig-1 mutant animals. Although the lack of a clear
FOXM1 homolog in C. elegans prevented further analysis
ofMELK/EZH2 signaling in the nematode, the data support
the results obtained withMELK and EZH2 in human GSCs.
An important therapeutic implication of the present data
is derived from the impact of MELK knockdown when
combined with IR for GSC-derived mouse xenografted tu-
mors. For decades, IR has been a mainstay of treatment
for GBM patients; however, the exact molecular mecha-
nisms that drive GBM radioresistance remain unclear.
Our data indicate that after IR, GSCs may become more
dependent on MELK-driven FOXM1/EZH2 signaling,
raising the possibility of novel therapeutic approaches for
GBM. EZH2 and FOXM1 are both oncogenic proteins
with substantially elevated expression in various cancers,
including GBM. Nonetheless, it is extremely challenging
to develop molecularly targeted therapeutics for transcrip-
tion factors. There are no established EZH2 targeting
therapies for any cancer, but a phase I clinical trial
(NCT02082977) using an EZH2 inhibitor, GSK2816126
(an analog of GSK126 used in this study), for relapsed/re-
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Figure 5. EZH2 Is a Direct Target of the MELK/FOXM1 Complex in GBM Spheres
(A) Correlation of FOXM1 and EZH2 mRNA expression by microarray analysis of HGGs (n = 76).
(B) FOXM1 mRNA expression in patients with good (>209 weeks survival, n = 19) versus poor (<52 weeks survival, n = 17) prognosis in the
Phillips et al. (2006) data set. Asterisk (*) indicates statistical significance by Student’s two-tailed t test. *p < 0.05.
(C) Heatmap of MELK, EZH2, and FOXM1 expression in GSCs after treatment with shNT control, shFOXM1, or shFOXM1 plus EZH2 over-
expression.
(D) Relative chemiluminescence of luciferase driven by the EZH2 promoter after infection of GBM spheres with GFP control, MELK
overexpression vector, or FOXM1 overexpression vector. MELK overexpression treatment was also combined with shFOXM1, and FOXM1
overexpression treatment was also combined with shMELK or shFOXM1. Data represent the mean ± SD from three independent experiments
and statistical significance was evaluated by one-way ANOVA followed by Bonferroni post hoc tests. GFP versus MELK, MELK+shFOXM1, or
FOXM1: ***p < 0.001; FOXM1 versus FOXM1+shFOXM1, FOXM1+shMELK#1, or FOXM1+shMELK#2: ###p < 0.001.
(E) Relative chemiluminescence of EZH2 promoter activity in GBM spheres after infection with GFP control or FOXM1 overexpression vector
and increasing doses of the FOXM1 inhibitor siomycin A (0.05–0.5 mM). Data represent the mean ± SD of triplicate experiments.
(F) Relative chemiluminescence of EZH2 promoter activity in GBM spheres after infection with GFP control or combinations of MELK wild-
type (WT) overexpression, FOXM1 binding-deficient MELK (MELK D150A), or FOXM1 overexpression. Data represent the mean ± SD of
triplicate experiments.
(G) Relative chemiluminescence of EZH2 promoter activity in GBM spheres after infection with GFP control or MELK, FOXM1 WT, and FOXM1
mutated overexpression vectors with increasing doses of the MELK inhibitor C1. Data represent the mean ± SD of triplicate experiments.
(H) ChIP for RNA pol II or FOXM1 followed by PCR for the EZH2 promoter. Data represent the mean ± SD of triplicate experiments. A
representative data set from three independent experiments is shown.
(I) ChIP for FOXM1 or IgG control at the EZH2 promoter after pretreatment of spheres with vehicle control, siomycin A, or C1. Data represent
the mean ± SD of triplicate experiments. A representative data set from three independent experiments is shown.
(J) Microarray analysis and qPCR validation of EZH2 targets in GSCs treated with shNT (control), shMELK, shFOXM1, and EZH2 over-
expression. The gene expression levels were validated by real-time RT-PCR. Data represent the mean ± SD from three independent
(legend continued on next page)
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lymphoma is currently ongoing. Our identification of the
protein kinase MELK as a key regulator of FOXM1-driven
EZH2 signaling in preclinical GBM tumors and GSCs may
facilitate the development of MELK-targeted therapies
that can lead to FOXM1/EZH2 deregulation in GBM. In
2013, a phase I clinical trial (NCT01910545) for non-CNS
cancers was started in order to test OTS167, a small-mole-
cule kinase inhibitor with high specificity for MELK.
Recently, we also identified C1 as a kinase inhibitor that
preferentially inhibits MELK (Minata et al., 2014). Given
that MELK knockdown strongly sensitizes GSC-derived
mouse tumors to IR, it is an attractive idea to combine IR
therapy with chemotherapy using a MELK inhibitor (and
possibly an EZH2 inhibitor) for GBM.
Our results suggest several open questions that will
require further investigation. Although evidence suggests
that eradication of cancer stem cells appears to be beneficial
for curing cancers, recent studies also suggest that non-
cancer stem cells acquire a cancer stem cell phenotype
when challenged by stressors such as glucose deprivation
(Flavahan et al., 2013). Thus, eradication of the existing
cancer stem cells may not be sufficient, and instead a
therapeutic combination targeting noncancer stem cells
in addition to cancer stem cells may be mandatory. The
IR-induced increases in MELK and EZH2 may be due to
(1) the preferential eradication of nonstem tumor cells
and subsequent enrichment of GSCs after treatment (i.e.,
selection of a therapy-resistant tumor cell population) or
(2) IR-induced phenotypic changes of the treated GBM
sphere cells, resulting in increasedMELK and subsequently
EZH2 through modulation of stress-induced enzymes
(plasticity of GSCs and non-GSCs). It is also possible that
both explanations are true. Future studies will address
this issue.
Another open question is, which GBM subtypes and
GSC subtypes are dependent on the MELK-FOXM1-EZH2
signaling axis? Thus far, recent genome-wide transcrip-
tome and methylome analyses support the existence of
three to six GBM subtypes (Phillips et al., 2006; Sturm
et al., 2012; Verhaak et al., 2010) and two GSC subtypes
(Bhat et al., 2013; Mao et al., 2013). It is not entirely clear
whether any of the GBM/GSC subtypes are more preferen-
tially dependent on the MELK-FOXM1-EZH2 axis or allexperiments and statistical significance was evaluated by one-way
shMELK, or shFOXM1: **p < 0.01,***p < 0.001; EZH2 versus shMELK+
(K) Flow-cytometric analysis for EZH2 of glioma spheres cultured in ne
in DC medium also included samples treated with FOXM1 overexpre
overexpression with or without GSK126 (middle panel). Spheres cultu
EZH2 overexpression vector (right panel).
(L) Flow-cytometric analysis of irradiated GBM spheres for Annexin V
EGFP control (left panel), FOXM1 overexpression vector (middle pane
See also Figure S5.
Stem Cellsubtypes rely equally on this signaling axis. Future studies
will address this question.
In conclusion, in this study, we identified a signaling
pathway for EZH2 upregulation inGSCs that plays a critical
role in GBM tumor propagation and radioresistance. Iden-
tification of the MELK/FOXM1 protein complex as the
predominant regulator for the EZH2 gene in GSCs high-
lights a possible therapeutic target for the devastating dis-
ease GBM.EXPERIMENTAL PROCEDURES
Glioma Tumor-Derived Neurospheres
All of the work related to human tissues was performed at The
Ohio State University and MD Anderson Cancer Center under
institutional review board-approved protocols according to NIH
guidelines. Glioma and normal neurospheres were derived from
19 HGG samples, three fetal-brain-derived astrocytes, and neural
progenitors as described previously (Bhat et al., 2013; Gu et al.,
2013; Guvenc et al., 2013; Miyazaki et al., 2012; Nakano et al.,
2011). For the Ohio State University samples, brain tumor resec-
tions were performed by Drs. I. Nakano and E.A. Chiocca (Depart-
ment of Neurological Surgery, The Ohio State University). In
brief, freshly resected glioma tumor samples were dissociated
into single cells using both mechanical (neurospheres were
gently pipetted with P1000 pipet tips four to five times) and enzy-
matic (TrypLE Express; Invitrogen) methods. The dissociated tu-
mor cells were cultured in Dulbecco’s modified Eagle’s medium
(DMEM)/F12 (Invitrogen) supplemented with B27 (1:50), heparin
(5 mg/ml), basic fibroblast growth factor (bFGF; 20 ng/ml), and
epidermal growth factor (EGF; 20 ng/ml). Growth factors (bFGF
and EGF) were added twice a week. For differentiation of GSCs,
neurospheres were cultured in DMEM/F12 supplemented with
10% (vol/vol) fetal bovine serum for 10 days. All of the neuro-
spheres analyzed in this study were cultured for <20 passages
from surgery or xenograft mouse intracranial tumors. In some ex-
periments, various neurospheres were exposed to radiation after
cells were plated at a density of 1 3 106 cells/flask 1 day before
radiation treatment.Gene Expression Omnibus Profile and TCGA
MELK and FOXM1 expression data (Affymetrix Human Genome
U133A Array) were downloaded from the GDS1815 data set and
analyzed for grade III glioma and GBM. The Cancer Genome AtlasANOVA followed by Bonferroni post hoc tests. shNT versus EZH2,
EZH2 or shFOXM1+EZH2: #p < 0.05, ##p < 0.01, ###p < 0.001.
urosphere (NS) or differentiation (DC) medium. Analysis of spheres
ssion with or without GSK126 (left panel), and MELK and FOXM1
red in NS medium were also treated with shFOXM1 or shFOXM1 plus
and propidium iodide. Irradiated spheres were treated with either
l), or FOXM1 overexpression with GSK126 (right panel).
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(TCGA) data are available through the TCGAData Portal at https://
tcga-data.nci.nih.gov/tcga/.
ChIP-PCR Analysis to Determine EZH2 Promoter
Occupancy
Using the Genomatrix program, we searched the consensus bind-
ing site in the human EZH2 promoter and performed ChIP-PCR
using the QIAGENChIP kit according to themanufacturer’s proto-
col. A total of 131 patient-derived GBMs were treated with either
C1 or siomycin A for 1 day and processed for genomic DNA
isolation.
C. elegans Culture and Strains
C. eleganswormswere grownat 20Connematodegrowthmedium
(NGM) plates seeded with OP50 E. coli bacteria under standard
laboratory conditions (Brenner, 1974) unless otherwise indicated.
The strains used in this study were obtained from the C. elegans
Genetic Center and included N2 Bristol (wild-type), NG4370
zdIs5; pig-1 (gm344) IV, and SS186 mes-2 (bn11), unc-4 (e120)/
mnC1, dpy-10 (e128), unc-52 (e444) II.
RNAi for C. elegans
RNAi experiments were performed using the feeding method
described in (Timmons, 2006). N2 worms were fed HT115 bacteria
strains containing pig-1 RNAi from the Ahringer library (Kamath
et al., 2003) or HT115 bacteria containing the empty L4440
feeding vector as a control. Bacteria were applied to plates con-
taining 1 mM isopropyl b-d-thiogalactoside (Sigma Aldrich) and
50 mg/ml ampicillin (Sigma Aldrich), and induced overnight at
room temperature. Synchronized L1 animals were put on the
plates, grown until young adulthood (20–24 hr after L4), and
then used for embryonic lethality experiments (see below).
The graph in Figure 3E is an average of at least three experiments
performed on three separate days, except for themes-2 (bn11); con-
trol (RNAi) experiment, which was repeated two times.
Embryonic Lethality Assay in C. elegans
Synchronized young adult worms (20–24 hr after L4 stage) were
treated with the indicated amounts of ionizing IR (Faxitron X-ray
machine) and allowed to recover for 24 hr. Thirty worms for
each variable were divided into ten worms/three plates and
allowed to lay eggs for 4–6 hr. After 24–48 hr, hatched and
unhatched progeny were counted with the use of a dissecting mi-
croscope to determine the percentage of embryonic lethality (un-
hatched eggs/total progeny). The experiment was performed in
triplicate on three separate days.
Quantification of Apoptosis in C. elegans
Apoptotic germlines were scored in young adult worms 24 hr
after IR treatment or in age-matched untreated controls using
AO (10 mg/ml; Molecular Probes) staining as described previously
(Craig et al., 2012). In brief, worms were removed from plates
with M9 buffer into a microfuge tube. Then, 200 ml of AO
(5 mL/ml) was added and the tubes were covered in foil and
incubated for 2 hr. The worms were placed on NGM plates with
food and then on slides with agarose pads. AO+ cells were236 Stem Cell Reports j Vol. 4 j 226–238 j February 10, 2015 j ª2015 The Acounted using the 403 objective on a fluorescence microscope
(Zeiss Imager M2).
Quantification of Mitotic Cells in C. elegans
Synchronized young adult pig-1 andN2worms grown at 25Cwere
fixedwithmethanol/acetone and stainedwith DAPI (100 ng/ml in
PBST). In brief, the worms were washed from the plates with M9
buffer and incubated in 20C methanol for 10 min, incubated
in 20C acetone for 5 min, washed one time in PBST, incubated
for 10 min in DAPI at room temperature, and washed two times
in PBST. Images of germlines were acquired with a 603 objective
on a fluorescence microscope (Zeiss Imager M2) and the mitotic
nuclei of optically bisected germlines were counted with the use
of ImageJ Micromanager software. Two independent experiments
were used for quantification.
The experimental methods used in this work are detailed in the
Supplemental Experimental Procedures.
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